Ginkgo Bioworks Holdings (DNA) EBT (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of EBT data on file, last reported at -$76.1 million in Q1 2026.

• Quarterly EBT rose 8.51% year-over-year to -$76.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$298.9 million (up 35.71% YoY) and the FY2025 annual result came in at -$313.6 million, up 42.72% from the prior year.
• EBT grew to -$76.1 million in Q1 2026, from -$81.4 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$56.8 million in Q3 2024 to a low of -$670.6 million in Q2 2022.
• A 5-year average of -$232.0 million and a median of -$173.2 million in 2023 frame the typical range for EBT.
• The widest YoY moves for EBT: up 88.3% in 2022, down 1121.63% in 2022.
• Tracing DNA's EBT over 5 years: stood at -$187.8 million in 2022, then fell by 12.8% to -$211.9 million in 2023, then soared by 49.1% to -$107.9 million in 2024, then increased by 24.54% to -$81.4 million in 2025, then gained by 6.46% to -$76.1 million in 2026.
• The last three EBT figures came in at -$76.1 million (Q1 2026), -$81.4 million (Q4 2025), and -$80.8 million (Q3 2025), per Business Quant data.